Replies to post #26449 on Mymetics Corp (MYMX)

[bow-tie]

A virosomal vaccine inducing systemic/mucosal anti-HIV-1 gp41 IgG/IgA had previously protected Chinese-origin rhesus macaques (RMs) against vaginal SHIVSF162P3 challenges. Here, we assessed its efficacy in Indian-origin RMs by intramuscular priming/intranasal boosting (n=12/group). Group K received virosome-P1-peptide alone (harboring the Membrane Proximal External Region), Group L combined virosome-rgp41 plus virosome-P1, and Group M placebo virosomes.

http://121.199.17.194/paper/1496195874951614464

[Phosphene]

Yes sir. Building calf immunity with mucosal vaccines.

Sylvain Fleury's Linkedin had some bovine specialists out of The Dakotas several months back.

Merck listed in your article link.

Jan Wilschut being on MYMX and Merck scientific advisory boards doesn't hurt.

Another potential revenue stream for MYMX with livestock.

[Phosphene]

"It should be noted that the challenge route was intravaginal – quite different from all other preclinical AIDS vaccine development studies that mostly used the intrarectal challenge route."

The current HIV virosomal vaccine MYM-V201 that has no added adjuvant can elicit a front-line mucosal defenses that could prevent male-to-female HIV transmission.

MIT, Dartmouth, Bern, Freddy Hutch and The Duke boys will get this fast tracked.

Funding
This work was supported by the Bill & Melinda Gates Foundation Grant OPP1111654 to RMR, NIH U19 AI142636 to RMR and SF, Collaboration for AIDS Vaccine Discovery, Vaccine Immune Monitoring Center (CAVIMC) grant OPP1146996, the National Institutes of Health/Office of Research Infrastructure Programs (NIH/ORIP) Grant P51 OD011133 to the Southwest National Primate Research Center (SNPRC) in San Antonio, TX, and National Institute of Allergy and Infectious Diseases (NIAID, Duke Center for AIDS Research (CFAR) grant P30 AI064518.